| 000 | 01827 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250515182952.0 | ||
| 264 | 0 | _c20091027 | |
| 008 | 200910s 0 0 eng d | ||
| 022 | _a1741-8275 | ||
| 024 | 7 |
_a10.1097/01.hjr.0000359233.58023.64 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGielen, Stephan | |
| 245 | 0 | 0 |
_aRisk factor management: antiatherogenic therapies. _h[electronic resource] |
| 260 |
_bEuropean journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology _cAug 2009 |
||
| 300 |
_aS29-36 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aCardiovascular Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCardiovascular Diseases _xetiology |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xcomplications |
| 650 | 0 | 4 |
_aDiet _xadverse effects |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aExercise |
| 650 | 0 | 4 | _aHealth Knowledge, Attitudes, Practice |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aLife Style |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRisk Reduction Behavior |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSandri, Marcus | |
| 700 | 1 | _aSchuler, Gerhard | |
| 700 | 1 | _aTeupser, Daniel | |
| 773 | 0 |
_tEuropean journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology _gvol. 16 Suppl 2 _gp. S29-36 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/01.hjr.0000359233.58023.64 _zAvailable from publisher's website |
| 999 |
_c19081252 _d19081252 |
||